HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Cardiff Oncology (NASDAQ:CRDF) but lowers the price target from $14 to $13.

August 08, 2023 | 11:23 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cardiff Oncology's price target has been lowered from $14 to $13 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100